• In late January 2026, Carda Health announced a partnership with Humana to expand at-home virtual cardiac rehabilitation and coordinated chronic-care services for older adults, while U.S. regulators proposed only a 0.09% payment increase for Medicare Advantage plans in 2027, far below analysts’ prior expectations.
• Together, these developments highlight how Humana is simultaneously facing pressure on Medicare Advantage economics and investing in digitally enabled care models through its partners and CenterWell platform.
• Next, we’ll examine how the surprisingly small Medicare Advantage payment proposal could reshape Humana’s investment narrative and long-term positioning.

These 14 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

What Is Humana's Investment Narrative?

To own Humana today, you have to believe that Medicare Advantage can still be a viable core business even as policymakers tighten the screws and the company shifts harder into integrated, tech-enabled care. The 0.09% proposed payment bump for 2027 is a clear hit to the short-term catalyst many investors were watching: a margin recovery story supported by mid-single-digit rate increases. Instead, pricing, benefit design, and cost control now look like the primary near-term battlegrounds, with the February 11 earnings call likely to reset expectations. At the same time, partnerships such as Carda Health and the build-out of CenterWell suggest Humana is leaning into care delivery and at-home models that could matter more over time. The catch is that these initiatives require capital just as returns on the Medicare Advantage book are under pressure.

However, investors should be aware that tighter Medicare Advantage economics may force tougher trade-offs on growth and benefits. Despite retreating, Humana's shares might still be trading above their fair value and there could be some more downside. Discover how much.

Exploring Other Perspectives

Nine Simply Wall St Community fair value views span roughly US$211.89 to a very large US$983.96, reflecting wide disagreement. Set against the recent Medicare Advantage shock, these contrasting opinions underline why understanding policy risk is crucial before forming a view on Humana’s long-term prospects.

Explore 9 other fair value estimates on Humana - why the stock might be worth over 5x more than the current price!

Build Your Own Humana Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Humana research is our analysis highlighting 5 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Humana research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Humana's overall financial health at a glance.

Ready For A Different Approach?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 31 best rare earth metal stocks of the very few that mine this essential strategic resource.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 24 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• Uncover the next big thing with financially sound penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.